Population demographics and treatment parameters
| Variable | Study population |
| n | 28 |
| Comorbidities | |
| Hypertension (%) | 22 (78.6) |
| Ischaemic heart disease (%) | 10 (35.7) |
| Atrial fibrillation (%) | 8 (28.6) |
| Congestive cardiac failure (%) If yes, NYHA class (IQR) | 7 (25.0) 3 (1–3) |
| Diabetes mellitus (%) | 15 (53.6) |
| Chronic kidney disease (%) If yes, stage (IQR) | 15 (53.6) 3b (3a–3b) |
| COPD (%) | 5 (17.9) |
| Bronchiectasis (%) | 1 (3.6) |
| Asthma (%) | 6 (21.4) |
| Active malignancy (%) | 3 (10.7) |
| Dementia (%) | 1 (3.6) |
| Stroke (%) | 2 (7.1) |
| Previous pulmonary or venous thromboembolism (%) | 2 (7.1) |
| Results from the acute admission | |
| Imaging ‘Classical’ (%) | 16 (57.1) |
| Imaging ‘Indeterminate’ (%) | 8 (28.6) |
| SpO2 prior to NIPS (IQR) | 89% (85–92.75) |
| Acute kidney injury (%) | 9 (32.1) |
| Acutely deranged liver function tests (%) | 4 (14.3) |
| NIPS parameters | |
| Received CPAP (%) | 23 (82.1) |
| Received BiPAP (%) | 5 (17.9) |
| CPAP max pressure cmH2O (SD) | 12.7 (2.1) |
| BiPAP maximum inspiratory pressure cmH2O (SD) | 22.4 (6.0) |
| BiPAP maximum expiratory pressure cmH2O (SD) | 10.2 (2.9) |
| BiPAP max back up rate (SD) | 13.2 (1.8) |
Data are presented as mean (SD) where parametric, median (IQR) where non-parametric, or absolute number (%) where categorical.
BiPAP, Bi-level Positive Airway Pressure ; COPD, Chronic Obstructive Pulmonary Disease; CPAP, Continuous Positive Airway Pressure; NHYA, New York Heart Association; NIPS, non-invasive pressure support; SpO2, Peripheral Oxygen Saturation.